Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects

What Was Tested

This randomized controlled trial paper looks at Semaglutide and Dulaglutide.

The primary endpoint was intensity of injection-site pain, measured using a visual analogue scale (VAS; 0 mm = no pain, 100 mm = unbearable pain).

Exploratory endpoints included intensity category, duration and quality of injection-site pain, and comparative assessment of injection-site pain with the two injections.

How the Study Was Run

The design is described as randomized, double-blind and crossover.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Semaglutide.

In the crossover set-up each of the participants took both Semaglutide and the comparison in turn, acting as their own control.

What Was Measured

The primary endpoint was intensity of injection-site pain, measured using a visual analogue scale (VAS; 0 mm = no pain, 100 mm = unbearable pain).

Exploratory endpoints included intensity category, duration and quality of injection-site pain, and comparative assessment of injection-site pain with the two injections.

The subject headings attached to it are Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Healthy Volunteers, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Recombinant Fusion Proteins and Semaglutide.

The authors tagged it with the keywords GLP-1 analogue, antidiabetic drug and clinical trial.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Semaglutide and Dulaglutide.

The publication is from 2021 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Semaglutide compound page and the Dulaglutide compound page.